Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.
Brands: https://events.jspargo.com/ASCO21/CUSTOM/Coherus_SocialMedia_Banners_LinkedIn.jpg
Show Specials
Press Releases
Products